follow initi long-term outcom data present aha discuss
attach tabl lead kol call recap believ bridgebio
van buren eido appear superior anticip blockbust vyndaqel/
tafamidi result decreas discount rate coupl point result
new price target stand-alone enterpris valu note
conserv multipl sale estim believ
attr cardiomyopathi market could grow eventu opportun pool
diagnos patient expand several-fold final includ premium
takeout believ becom like follow data bottom line
recommend investor buy share strength make core long-
kol call recap note discuss vyndaqel launch proceed well
higher diagnosi rate like improv educ increas
non-invas imag kol current prescrib vyndaqel/tafamidi
attr-cm patient state insur coverag reimburs
easier anticip attain addit complianc high
patient terrifi die kol note class patient
expect surviv year note comment jive well impress
sale uncov report first full quarter post
launch record ytd consensu approach earli
number give us high level confid estim market opportun discuss
moreov oppos sever year ago kol note attr-cm
becom attract field young cardiologist diseas awar
commun all-tim high continu increas therefor
direct result improv patient physician educ increas use non-
invas diagnost imag kol believ diagnosi rate
easili doubl tripl next decad state alreadi evid practic
number physician treat attr-cm patient tripl last three year
clinic develop risk attr cardiomyopathi cm
eido leader field ttr stabil
dcf includ
eu us japan attr
cardiomyopathi polyneuropathi
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
patient
type diseas
hierarch all-caus mortal hospit
frequenc cardiovascular-rel hospit
patient
lead discontinu
type advers event
grade higher teae
piper jaffray compani report variou sourc per
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
good sold
revenu
revenu
revenu
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
